Please ensure Javascript is enabled for purposes of website accessibility

These Biotech Investors Are Far From Depressed

By Brian Orelli, PhD - Apr 17, 2013 at 3:07PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Alkermes' ALKS 5461 produces positive phase 2 data in depressed patients.

Alkermes (ALKS 1.49%) is up big today on phase 2 data suggesting that its depression drug ALKS 5461 works.

The drug produced a statistically significant improvement in three different rating scales for depression compared to placebo. Alkermes didn't add any numbers to the top-line data; it's saving them for a medical meeting at the end of next month.

Clinical trials for depression are notoriously hard to run because of high placebo effect. It'll be interesting to see if ALKS 5461 was statistically significant because Alkermes was able to keep the placebo group in check or if the drug just blew away the typically high placebo.

A taming of the placebo effect would be good for the development of depression drugs, but we'll have to see if Alkermes can repeat it in a larger phase 3 trial. If ALKS 5461 is just super powerful, it's easier to see how the data could be reproduced in the next trial.

Alkermes is testing ALKS 5461 in patients who have already failed a selective serotonin reuptake inhibitor, such as Pfizer's (PFE 0.44%) Zoloft, or a serotonin-norepinephrine reuptake inhibitor, such as Eli Lilly's (LLY 1.03%) Cymbalta. In theory that makes it harder to prove efficacy, but it also makes it much easier to sell the drug because it won't be in direct competition with those drugs, especially considering the large number of generic drugs available.

The second-line market isn't quite as big as the market for new-to-treatment patients, but more than half of depressed patients don't respond to the first drug they're prescribed. Alkermes would be happy if it can grab a large fraction of the market; Cymbalta registered sales of $5 billion last year and Zoloft managed $3.3 billion in the last year before it went generic.

ALKS 5461 might even be able to be used in combination with current treatments because it works using a novel mechanism of action, blocking the kappa opioid receptor. While that could open it up to additional sales -- AstraZeneca's (AZN 0.01%) Seroquel XR, a $1.5 billion drug, is used in combination with other drugs to treat depression -- the new mechanism will also bring additional scrutiny over the side effects. Alkermes described the drug as "well tolerated" but didn't go into greater detail.

Without a doubt, the top-line data should have investors doing the happy dance, but be careful penciling in sales just yet. A failure at the phase 3 level will certainly depress the stock and investors alike.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Alkermes plc Stock Quote
Alkermes plc
$29.28 (1.49%) $0.43
Pfizer Inc. Stock Quote
Pfizer Inc.
$53.95 (0.44%) $0.23
AstraZeneca PLC Stock Quote
AstraZeneca PLC
$66.82 (0.01%) $0.01
Eli Lilly and Company Stock Quote
Eli Lilly and Company
$310.16 (1.03%) $3.15

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.